Solving Complex Diseases at the Genomics Level

Decoding the Language of Life

Cognit is building foundational AI to simulate Gene Regulatory Networks, transforming how genes are understood and controlled.

Cognit's Innovation

Cognit is working on a cross-cell, cross-species model in generative biology aimed at simulating gene regulatory networks and supporting high-resolution functional genomics through closed-loop, in-silico gene and cell engineering. We hope this can eventually contribute to new approaches in genomics research.

This is extremely challenging work and we are still at an early research stage. Many of our models and approaches are actively discarded as we learn what holds and what does not.

The current state of drug discovery is inefficient and expensive. It takes an average of 12 years and $2.6 billion to bring a new drug to market.

This is due in part to the fact that drug discovery is largely a trial-and-error process. Researchers must first identify a target gene, then develop a drug that can modulate that gene's expression. This process is often time-consuming and expensive, and it can be difficult to predict which drugs will be effective.

Cognit's Eventual Focus

High-Resolution Genomics: We aim to advance traditional views, aspiring to achieve significant insights into genetic interactions.

Phenotype Prediction: We are developing methods to accurately predict phenotypes from genotypes, enhancing our understanding of genetic expression and its implications.

Novel Biomarker Discovery: We are identifying novel biomarkers to facilitate early diagnosis and targeted treatments.

Episomal Gene Synthesis: We are advancing episomal gene synthesis techniques to improve gene therapy outcomes.

Ex-vivo and In-vivo Design: We are pioneering ex-vivo and in-vivo design strategies to enhance precision in genetic engineering and therapeutic applications.